| ²é¿´: 1769 | »Ø¸´: 9 | |||||||||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||||||||||
[½»Á÷]
ÄÉ˹´ï¿ËÉÏÊÐÍâÆóÕÐÆ¸CRAÒ»Ãû
|
|||||||||||
ְλ: ÁÙ´²¼à²éÔ± ÈÎÖ°×ʸñ£º • ÉúÃü¿ÆÑ§Ïà¹Ø×¨Òµ´óר¼°ÒÔÉÏѧÀú • ¾ßÓÐ2ÄêÒÔÉϵÄCRA¡¢CRC»òÁÙ´²ÊÔÑéCRO¹«Ë¾µÄÏà¹Ø¹¤×÷¾Ñ飬ÓÐÖ×ÁöÁÙ´²Ñо¿¼à²é¹¤×÷¾ÀúÕßÓÅÏÈ • ÊìϤI/IIÆÚÁÙ´²ÊÔÑé¾ßÌåÁ÷³ÌºÍGCP¼°CFDAµÄÏà¹Ø·¨ÂÉ·¨¹æ£»ÓÐÍâ×ÊÒ©³§»ò¹ú¼Ê¶àÖÐÐÄÏîÄ¿¾ÑéÕßÓÅÏÈ • ½ÏÇ¿µÄÈ˼ʹµÍ¨Óë×éÖ¯¹ÜÀí¼¼ÇÉ£¬¾ßÓÐÁ¼ºÃµÄ¹µÍ¨ºÍе÷ÄÜÁ¦£¬ÉÆÓÚ´¦ÀíÓëÁÙ´²Ñо¿ÖÐÐŤ×÷ÈËÔ±µÄ¹ØÏµ£¬ • ¾ßÓÐÁ¼ºÃµÄÖ°ÒµµÀµÂ¼°½ÏÇ¿µÄÔðÈÎÐÄ£¬¾ßÓжÀÁ¢¹¤×÷µÄÄÜÁ¦ ְλÃèÊö: • ²ÎÓëÖ´ÐÐÖÐÐÄÑ¡Ôñ¼°±ê×¼ÆÀ¼Û¹¤×÷£¬ÐÖúÁÙ´²ÊÔÑéµÄ×¼±¸¡¢Æô¶¯¡¢ÊµÊ©ºÍ¼à²é¹ÜÀí¹¤×÷£¬Ðµ÷×éÖ¯Ñо¿Õß»áÒ飻 • Ö´ÐÐÖÐÐÄÆô¶¯¼°¹Ø±Õ£¬ÅàѵµÈÏà¹Ø¹¤×÷£¬¶Ô¸÷Ñо¿ÖÐÐÄʵʩ³£¹æ·ÃÊÓ£¬ÔÚÑо¿ÖÐÐÄÓëÏîÄ¿¹ÜÀíÍŶÓÖ®¼ä±£³ÖÁ¼ºÃÓÐЧµÄ¹µÍ¨½»Á÷£¬ÎªÑо¿ÕßÌṩÓмÛÖµµÄ½¨ÒéºÍ°ïÖú¼°Ê±·´Ó³²¢½â¾ö´æÔÚµÄÎÊÌ⣻±£³ÖÓëËùÓÐÑо¿ÕßÖ®¼äÁ¼ºÃµÄºÏ×÷¹ØÏµ£¬Ðµ÷ÊÔÑé¸÷·½¹ØÏµ£»È·±£Ñо¿ÖÐÐĵĸ÷Ï×÷·ûºÏGCP£¬ICH¼°SOPµÈ¸÷Ïî·¨¹æÖƶÈÒªÇó¡£ • ºË²éÑо¿ÖÐÐĵÄÔʼÊý¾Ý£¬×¼±¸¡¢ÊÕ¼¯ËùÓÐÑо¿ÖÐÐÄÏà¹ØµÄÎļþ£¬½â¾ö¸÷ÖÖÓëÖ®Ïà¹ØµÄÎÊÌ⼰ʱ´¦Àí¸÷ÀàÊÔÑéÏà¹ØµÄÎÊÌ⣬ȷ±£ÁÙ´²ÊÔÑéÊý¾Ý¿ÆÑ§¿É¿¿²¢¼°Ê±ÊÕ¼¯£¬È·±£CRF¼Ç¼׼ȷ¡¢ÍêÕû£¬½øÐÐÔʼÊý¾ÝµÄºË¶Ô£¬°´ÒªÇó¼°Ê±Íê³É¼à²é±¨¸æ¡£ • е÷CROºÍ¸÷Ñо¿ÖÐÐĵŤ×÷£¬ÒÔÈ·±£°´ÕÕʱ¼ä±íÍê³É²¡ÀýµÄÈë×鹤×÷£¬È·±£Ñо¿ÖÐÐĵĽøÕ¹·ûºÏÑо¿¼Æ»®½ø¶ÈÒªÇó£» ÎÒÃǽ«Ìṩ¸øÔ±¹¤£º Á¼ºÃ¹¤×÷·ÕΧ ÎåÏÕÒ»½ðµÈн×ʸ£Àû´ýÓö ¸÷ÖÖÅàѵºÍ·¢Õ¹¿Õ¼ä Ó¢´´Ô¶´ï£¨±±¾©£©ÉúÎïÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾³ÉÁ¢ÓÚ2012Äê8Ô¡£ÎªÃÀ¹úNASDAQÉÏÊй«Ë¾,Ŀǰ¹«Ë¾¹É·ÝÔ¼2200Íò¹É£¬ÊÐÖµÔ¼3000ÍòÃÀÔª¡£ÖÂÁ¦ÓÚС·Ö×Ó°ÐÏòÖÎÁÆÖ×Áö¡¢×ÔÉíÃâÒß²¡µÄÐÂÒ©¿ª·¢¡£¹«Ë¾ÔÚÃÀ¹úÂíÀïÀ¼ÖÝÉèÓÐ×ܲ¿¡£°ì¹«µØµãΪ±±¾©Êг¯ÑôÇø¶«Èý»·£¬¹«Ë¾Ä¿Ç°ÔÚº£µíÇøÉèÁ¢ÊµÑéÊÒÖÂÁ¦ÓÚÐÂÒ©Ñз¢¡£ ĿǰÓÐ2¸ö²úÆ·ÔÚÃÀ¹ú¾FDAÅú×¼½øÈëÁÙ´²Ñо¿×¨×¢Ð¡·Ö×Ó°ÐÏòÖÎÁÆÖ×Áö¡¢×ÔÉíÃâÒßµÄÐÂÒ©¿ª·¢£¬Ä¿Ç°ÒÑÓп¹ÈéÏÙ°©Ò»ÀàÐÂÒ©½øÈëIIÆÚÁÙ´²Ñо¿½×¶Î¡£ Ö÷ÒªÑо¿ÕßJennifer R. Diamond, ҽѧ²©Ê¿£¬ÃÀ¹ú¿ÆÂÞÀ¶à´óѧҽѧԺ Ö×ÁöÑо¿ÖÐÐÄ£¬ÃÀ¹úÖøÃûÈéÏÙ°©×¨¼Ò¡£Ö÷ÒªÑо¿ÕßKathy Miller, MD£¬Ò½Ñ§²©Ê¿£¬ÃÀ¹úÓ¡µÚ°²ÄÉ´óѧҽѧԺ Ö×ÁöÑо¿ÖÐÐÄ£¬ÃÀ¹úÖøÃûÈéÏÙ°©×¨¼Ò¡£ Ö´Ðжʳ¤Wei-wu He ²©Ê¿£¬IDG×ʱ¾·çÏÕͶ×ʺϻïÈË£¬°ÁÈñ¶«Ô´£¨ÃÀ¹ú¡¢±±¾©¡¢ÎÞÎý£©¹«Ë¾¶Ê³¤¡¢Ê×ϯִÐй٣¬¹þ·ð´óѧ²©Ê¿ºó£¬±´ÀÕҽѧԺ²©Ê¿£¬ÃÀ¹úÎÖ¶ÙÉÌѧԺ¹¤É̹ÜÀí˶ʿ¡£ Ê×ϯִÐй٣¬Ken Ren ²©Ê¿£¬ÃÀ¹úÂå¿Ë·ÆÀÕ´óѧ²©Ê¿ºó£¬Å¦Ô¼ÖÝÁ¢´óѧ²©Ê¿£¬Ç廪´óѧÖйúÆóÒµ¼Ò׿ԽÁìµ¼È˸߼¶ÑÐÐÞ°àÓÅÐãѧԱ¡£ ¹«Ë¾Ä¿Ç°ÔÚ±±¾©Êк£µíÇøÖйشåÉúÎïÒ½Ò©ÔºÉèÁ¢ÊµÑéÊÒ£¬½øÐÐÐÂÒ©Ñз¢µÈÏîÄ¿¡£ CASI Pharmaceuticals¹«Ë¾ÊÇÈ«ÃÀ°©Ö¢Ñо¿»ù½ð»á°ä·¢µÄµÚÆß½ìÊ¥½Ý¶û¼ªµÄ×î´óÔÞÖúÉÌ¡£ CASI Pharmaceuticals, Inc. is a NASDAQ listed public company with a stock code: CASI. It is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global oncology market. Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor, has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, and is currently completing a multi-center Phase 2 study in ovarian cancer. The Company has a wholly owned subsidiary, CASI Pharmaceuticals (Beijing) Co. Ltd., in Beijing, China with headquarters in Chaoyang business district. Additional information about CASI Pharmaceuticals is available on the Company's web site at www.casipharmaceuticals.com. Ó¢´´Ô¶´ï£¨±±¾©£©ÉúÎïÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾ µØ Ö·£º³¯ÑôÇøÏò¾ü±±Àï28ºÅÔº1ºÅÂ¥716ÊÒ ÓÊÕþ±àÂ룺100020 ÓÐÒâÏòµÄ¿ÉÒÔ·¢ËÍÓʼþµ½tomz@casipharmaceuticals.com »òÕß gloryli@casipharmaceuticals.com |
» ²ÂÄãϲ»¶
µ÷¼ÁÇóÊÕÁô
ÒѾÓÐ6È˻ظ´
272·Ö²ÄÁÏ×ÓÇóµ÷¼Á
ÒѾÓÐ36È˻ظ´
275Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸211£¬»¯Ñ§Ñ§Ë¶£¬310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á
ÒѾÓÐ20È˻ظ´
070300»¯Ñ§Ñ§Ë¶311·ÖÇóµ÷¼Á
ÒѾÓÐ19È˻ظ´
²ÄÁÏÓ뻯¹¤µ÷¼Á
ÒѾÓÐ13È˻ظ´
²ÄÁÏÓ뻯¹¤µ÷¼Á
ÒѾÓÐ33È˻ظ´
¸´ÊÔµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸¹þ¹¤´ó 085600 277 12²Ä¿Æ»ùÇóµ÷¼Á
ÒѾÓÐ17È˻ظ´
»¹Óл¯¹¤¶þÂÖµ÷¼ÁµÄѧУÂð
ÒѾÓÐ47È˻ظ´
|
3Â¥2014-07-10 14:27:04
4Â¥2014-07-10 22:32:00
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
7Â¥2014-07-11 12:44:53
LuciferZero
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 27 (СѧÉú)
- ½ð±Ò: 3488
- É¢½ð: 781
- ºì»¨: 5
- Ìû×Ó: 577
- ÔÚÏß: 1169.4Сʱ
- ³æºÅ: 1353570
- ×¢²á: 2011-07-22
- ÐÔ±ð: GG
- רҵ: ºÏ³ÉÒ©Îﻯѧ
8Â¥2014-07-15 07:10:07













»Ø¸´´ËÂ¥
10